![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Merck Vaccine Trial Halted After Encephalitis Case
Merck Vaccine Trial Halted After Encephalitis Case
April 6, 2010
Merck Serono, a division of Merck KGaA, has suspended enrollment and treatment of patients in ongoing worldwide studies of its therapeutic vaccine Stimuvax, following a suspected unexpected serious adverse reaction (SUSAR). The FDA placed a clinical hold on the investigational NDA for Stimuvax (BLP25 liposome vaccine), which is now in Phase III for non-small cell lung cancer and breast cancer. Investigators observed the SUSAR in a Phase II exploratory trial evaluating the drug in combination with cyclophosphamide in patients with multiple myeloma.
Clinical Trials Advisor
Clinical Trials Advisor
Upcoming Events
-
21Oct